Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. NVN Liquidation's annualizedGross Profit for the quarter that ended in Mar. 2023 was $6.84 Mil.
NVN Liquidation's average Total Assets over the quarter that ended in Mar. 2023 was $85.06 Mil. Therefore, NVN Liquidation's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2023 was 8.05%.
NVN Liquidation Gross-Profit-to-Asset % Historical Data
The historical data trend for NVN Liquidation's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of NVN Liquidation's Gross-Profit-to-Asset %
For the Biotechnology subindustry, NVN Liquidation's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NVN Liquidation's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NVN Liquidation's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where NVN Liquidation's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Mar. 2023) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
NVN Liquidation Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of NVN Liquidation's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
NVN Liquidation (NVN Liquidation) Business Description
NVN Liquidation Inc Formerly Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NOVNQ has been successfully added to your 